Clinical challenges and strategies on delivery of Oncolytic Virus
DOI:
https://doi.org/10.54097/avck7547Keywords:
Oncolytic Virus; Systematic delivery; Viral vector.Abstract
Oncolytic Virus therapy, including HSV-1 and adenovirus, is a new type of tumour immunotherapy that uses specific viruses to directly kill tumour cells or to induce the body's intrinsic and acquired immunity to generate anti-tumour immune responses. In addition, Oncolytic Virus is capable of recruiting immune cells to improve the tumour microenvironment, so the development of The clinical significance of oncolytic virus therapy lies in its potential to enhance the efficacy of other immunotherapeutic approaches. However, the delivery of Oncolytic Virus in current clinical trials has huge defects, which greatly limits the benefits of Oncolytic Virus and even produces certain side effects. Therefore, this review discusses the definition and mechanism of Oncolytic Virus and focuses on the defects in Oncolytic Virus delivery, such as systemic delivery and intratumoural delivery. Further, this review also summarizes some improvement strategies against the challenges of intratumoural heterogeneity and vascular complexity.
Downloads
References
H.L. Kaufman, F.J. Kohlhapp, A. Zloza, Oncolytic viruses: a new class of immunotherapy drugs, Nature reviews. Drug discovery, 14 (2015) 642-662.
T. Todo, H. Ito, Y. Ino, H. Ohtsu, Y. Ota, J. Shibahara, M. Tanaka, Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial, Nature medicine, 28 (2022) 1630-1639.
R.H.I. Andtbacka, F. Collichio, K.J. Harrington, M.R. Middleton, G. Downey, K. Ӧhrling, H.L. Kaufman, Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma, Journal for immunotherapy of cancer, 7 (2019) 145.
Z.J. Xia, J.H. Chang, L. Zhang, W.Q. Jiang, Z.Z. Guan, J.W. Liu, Y. Zhang, X.H. Hu, G.H. Wu, H.Q. Wang, Z.C. Chen, J.C. Chen, Q.H. Zhou, J.W. Lu, Q.X. Fan, J.J. Huang, X. Zheng, [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus], Ai zheng = Aizheng = Chinese journal of cancer, 23 (2004) 1666-1670.
L. Vidal, H.S. Pandha, T.A. Yap, C.L. White, K. Twigger, R.G. Vile, A. Melcher, M. Coffey, K.J. Harrington, J.S. DeBono, A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 14 (2008) 7127-7137.
S.J. Russell, K.W. Peng, J.C. Bell, Oncolytic virotherapy, Nature biotechnology, 30 (2012) 658-670.
X. Li, X. Sun, B. Wang, Y. Li, J. Tong, Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions, Asian journal of pharmaceutical sciences, 18 (2023) 100771.
N.H. Goradel, B. Negahdari, S. Ghorghanlu, S. Jahangiri, A. Arashkia, Strategies for enhancing intratumoral spread of oncolytic adenoviruses, Pharmacology & therapeutics, 213 (2020) 107586.
L. Li, S. Liu, D. Han, B. Tang, J. Ma, Delivery and Biosafety of Oncolytic Virotherapy, Frontiers in oncology, 10 (2020) 475.
S. Guedan, J.J. Rojas, A. Gros, E. Mercade, M. Cascallo, R. Alemany, Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth, Molecular therapy : the journal of the American Society of Gene Therapy, 18 (2010) 1275-1283.
Y. Zhang, J. Wu, H. Zhang, J. Wei, J. Wu, Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor, Frontiers in bioengineering and biotechnology, 8 (2020) 574007.
L. Evgin, T. Kottke, J. Tonne, J. Thompson, A.L. Huff, J. van Vloten, M. Moore, J. Michael, C. Driscoll, J. Pulido, E. Swanson, R. Kennedy, M. Coffey, H. Loghmani, L. Sanchez-Perez, G. Olivier, K. Harrington, H. Pandha, A. Melcher, R.M. Diaz, R.G. Vile, Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice, 14 (2022) eabn2231.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
